Oric Pharmaceuticals Stock Market Outlook
| ORIC Stock | USD 10.42 0.46 4.62% |
About 59% of Oric Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Oric Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Oric Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Oric Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Comfort Level 41
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Oric Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Oric Pharmaceuticals.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentDisposing |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Oric Pharmaceuticals is 'Sell'. Macroaxis provides Oric Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ORIC positions.
Execute Oric Pharmaceuticals Advice
The Oric recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Oric Pharmaceuticals. Macroaxis does not own or have any residual interests in Oric Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Oric Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Sell
Market Performance | Weakest | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Oric Pharmaceuticals has a Mean Deviation of 2.96, Standard Deviation of 4.04 and Variance of 16.31Our trade recommendations tool can cross-verify current analyst consensus on Oric Pharmaceuticals and to analyze the firm potential to grow in the current economic cycle. To make sure Oric Pharmaceuticals is not overpriced, please check all Oric Pharmaceuticals fundamentals, including its price to book, debt to equity, target price, as well as the relationship between the cash and equivalents and cash flow from operations . Given that Oric Pharmaceuticals has a number of shares shorted of 21.14 M, we recommend you to check out Oric Pharmaceuticals market performance and probability of bankruptcy to ensure the company can sustain itself in the current economic cycle given your recent risk tolerance and investing horizon.
Oric Pharmaceuticals Trading Alerts and Improvement Suggestions
| Oric Pharmaceuticals generated a negative expected return over the last 90 days | |
| Oric Pharmaceuticals has high historical volatility and very poor performance | |
| Oric Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (127.85 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oric Pharmaceuticals currently holds about 227.06 M in cash with (112.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.74. | |
| Oric Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 93.0% of the company shares are owned by institutional investors | |
| Latest headline from globenewswire.com: ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 |
Oric Pharmaceuticals current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Oric analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Oric analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Oric Pharmaceuticals Returns Distribution Density
The distribution of Oric Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Oric Pharmaceuticals' future price movements. The chart of the probability distribution of Oric Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Oric Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Oric Pharmaceuticals returns is essential to provide solid investment analysis for Oric Pharmaceuticals.
| Mean Return | -0.22 | Value At Risk | -6.13 | Potential Upside | 8.28 | Standard Deviation | 4.04 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Oric Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Oric Stock Institutional Investors
| Shares | Point72 Asset Management, L.p. | 2025-06-30 | 2.9 M | T. Rowe Price Associates, Inc. | 2025-06-30 | 2.8 M | Fmr Inc | 2025-06-30 | 2.5 M | First Turn Management Llc | 2025-06-30 | 2 M | Silverarc Capital Management, Llc | 2025-06-30 | 1.8 M | Balyasny Asset Management Llc | 2025-06-30 | 1.8 M | Mpm Oncology Impact Management Lp | 2025-06-30 | 1.7 M | State Street Corp | 2025-06-30 | 1.6 M | Ecor1 Capital, Llc | 2025-06-30 | 1.6 M | Nextech Invest, Ltd. | 2025-06-30 | 7.2 M | Vr Adviser, Llc | 2025-06-30 | 6.6 M |
Oric Pharmaceuticals Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Investments | 159.4M | (107.2M) | (43.4M) | 22.1M | 25.5M | 26.7M | |
| Change In Cash | 148.0M | (159.2M) | (43.4M) | 36.0M | 32.4M | 34.0M | |
| Free Cash Flow | (60.5M) | (77.2M) | (86.5M) | (113.9M) | (102.5M) | (97.3M) | |
| Depreciation | 897K | 966K | 1.0M | 1.1M | 1.3M | 1.1M | |
| Other Non Cash Items | 1.4M | (1.0M) | (6.1M) | (8.1M) | (7.3M) | (6.9M) | |
| Capital Expenditures | 939K | 2.1M | 849K | 1.2M | 1.4M | 1.0M | |
| Net Income | (78.7M) | (89.1M) | (100.7M) | (127.8M) | (115.1M) | (109.3M) | |
| End Period Cash Flow | 226.5M | 67.3M | 23.9M | 59.9M | 68.9M | 84.4M | |
| Change To Netincome | 1.1M | 25.4M | 12.9M | 14.5M | 16.7M | 10.0M |
Oric Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Oric Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Oric Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Oric stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.33 | |
β | Beta against Dow Jones | 1.30 | |
σ | Overall volatility | 4.17 | |
Ir | Information ratio | -0.08 |
Oric Pharmaceuticals Volatility Alert
Oric Pharmaceuticals exhibits very low volatility with skewness of 0.6 and kurtosis of 1.18. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Oric Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Oric Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Oric Pharmaceuticals Fundamentals Vs Peers
Comparing Oric Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Oric Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Oric Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Oric Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Oric Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Oric Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Oric Pharmaceuticals to competition |
| Fundamentals | Oric Pharmaceuticals | Peer Average |
| Return On Equity | -0.4 | -0.31 |
| Return On Asset | -0.25 | -0.14 |
| Current Valuation | 749.46 M | 16.62 B |
| Shares Outstanding | 97.39 M | 571.82 M |
| Shares Owned By Insiders | 6.71 % | 10.09 % |
| Shares Owned By Institutions | 93.29 % | 39.21 % |
| Number Of Shares Shorted | 21.14 M | 4.71 M |
| Price To Book | 2.54 X | 9.51 X |
| EBITDA | (126.74 M) | 3.9 B |
| Net Income | (127.85 M) | 570.98 M |
| Cash And Equivalents | 227.06 M | 2.7 B |
| Cash Per Share | 5.74 X | 5.01 X |
| Total Debt | 3.18 M | 5.32 B |
| Debt To Equity | 0.05 % | 48.70 % |
| Current Ratio | 18.72 X | 2.16 X |
| Book Value Per Share | 4.18 X | 1.93 K |
| Cash Flow From Operations | (112.66 M) | 971.22 M |
| Short Ratio | 12.10 X | 4.00 X |
| Earnings Per Share | (1.71) X | 3.12 X |
| Target Price | 21.0 | |
| Number Of Employees | 106 | 18.84 K |
| Beta | 1.33 | -0.15 |
| Market Capitalization | 970 M | 19.03 B |
| Total Asset | 274.14 M | 29.47 B |
| Retained Earnings | (562.77 M) | 9.33 B |
| Working Capital | 237.4 M | 1.48 B |
| Net Asset | 274.14 M |
Note: Acquisition by Chacko Jacob of 112500 shares of Oric Pharmaceuticals subject to Rule 16b-3 [view details]
Oric Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Oric . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 124913.0 | |||
| Daily Balance Of Power | 0.6866 | |||
| Rate Of Daily Change | 1.05 | |||
| Day Median Price | 10.33 | |||
| Day Typical Price | 10.36 | |||
| Price Action Indicator | 0.32 | |||
| Period Momentum Indicator | 0.46 |
Oric Pharmaceuticals Target Price Consensus
Oric target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Oric Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 12 | Strong Buy |
Most Oric analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Oric stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Oric Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationOric Pharmaceuticals Target Price Projection
Oric Pharmaceuticals' current and average target prices are 10.42 and 21.00, respectively. The current price of Oric Pharmaceuticals is the price at which Oric Pharmaceuticals is currently trading. On the other hand, Oric Pharmaceuticals' target price is what analysts think the stock is worth. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Oric Pharmaceuticals Market Quote on 7th of February 2026
Target Price
Analyst Consensus On Oric Pharmaceuticals Target Price
Oric Pharmaceuticals Analyst Ratings
Oric Pharmaceuticals' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Oric Pharmaceuticals stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Oric Pharmaceuticals' financials, market performance, and future outlook by experienced professionals. Oric Pharmaceuticals' historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
About Oric Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Oric Pharmaceuticals? Buying financial instruments such as Oric Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Oric Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Commodities Funds Thematic Idea Now
Commodities Funds
Funds or Etfs investing in commodities such as oil, gold, corn, soy, and agricultural goods. The Commodities Funds theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Commodities Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Oric Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Will Biotechnology sector continue expanding? Could Oric diversify its offerings? Factors like these will boost the valuation of Oric Pharmaceuticals. Anticipated expansion of Oric directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Oric Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Oric Pharmaceuticals's market price often diverges from its book value, the accounting figure shown on Oric's balance sheet. Smart investors calculate Oric Pharmaceuticals' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Oric Pharmaceuticals' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Oric Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Oric Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Oric Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.